The Hidden Cost of Health: Why Australians Pay More for Medical Devices
There’s a saying in healthcare: “The price of something is often not the cost of everything.” And nowhere is this truer than in Australia’s medical device market. Buried in a 10,000-item list called the Prescribed List, a quiet agreement made in 2022 has locked millions of privately insured Australians into paying some of the highest prices in the world for surgical hardware. But what’s most striking—and, frankly, infuriating—is how little attention this issue has received.
Personally, I think this story is a masterclass in how policy decisions, often made behind closed doors, can have far-reaching consequences for everyday people. It’s not just about the numbers; it’s about the systemic failure to prioritize patients over profits. Let me break it down for you.
The Deal That Defied Logic
In the weeks leading up to the 2022 federal election, then-health minister Greg Hunt struck a deal that set a mandatory price floor for medical devices in the private sector—7% above what public hospitals pay. On the surface, this might seem like a minor detail. But dig deeper, and you’ll find a system that isolates medical device manufacturers from competition, effectively funneling billions from policyholders to corporate coffers.
What makes this particularly fascinating is the sheer audacity of it. Federal bureaucrats explicitly warned Hunt that the deal would benefit industry at the expense of consumers. Yet, it was signed anyway. And when Labor took office, they didn’t dismantle it—they endorsed it. This raises a deeper question: Why do both major parties seem so reluctant to challenge a system that’s clearly broken?
The Price Gap That Tells a Story
Here’s a detail that I find especially interesting: For the most popular implanted cardiac defibrillator, private insurers paid $36,500 in 2023. Public hospitals paid $14,500 for the exact same device. That’s a markup of over 150%. And this isn’t an isolated case. From pacemakers to artificial joints, Australians are paying up to three times more than patients overseas.
If you take a step back and think about it, this isn’t just about money—it’s about trust. Australians are told that private health insurance offers better access to care, but what it often delivers is higher costs without commensurate benefits. What this really suggests is that the system is designed to maximize profit, not health outcomes.
The Politics of Inaction
One thing that immediately stands out is the lack of political will to fix this. Hunt defends his deal by claiming it put downward pressure on insurance premiums. But the data tells a different story. While prices for some devices have fallen, total outlays remain high, partly because hospitals are using more devices per procedure. In other words, the savings aren’t being passed on to consumers.
From my perspective, this is a classic example of regulatory capture. The medical device industry has successfully lobbied to maintain a system that works in its favor, while policymakers look the other way. What many people don’t realize is that this isn’t just a financial issue—it’s a moral one. Every dollar wasted on inflated device costs is a dollar that could be spent on improving patient care.
The Broader Implications
This issue isn’t just about Australia; it’s a symptom of a global trend. In many countries, healthcare costs are spiraling out of control, driven by opaque pricing and weak regulation. But Australia’s case is particularly egregious because it’s a deliberate policy choice, not an accident.
What this really suggests is that we need a fundamental rethink of how we fund and regulate healthcare. Why should medical devices be treated differently from prescription medicines, where the government negotiates directly with manufacturers to secure the lowest prices? The answer, I suspect, lies in the power of industry lobbying and the inertia of the political system.
A Call for Change
In my opinion, the first step to fixing this mess is transparency. The Prescribed List should be subject to rigorous international benchmarking, as recommended by the 2025 Nous Group report. But transparency alone isn’t enough. We need policymakers with the courage to challenge the status quo and prioritize patients over profits.
What makes this particularly urgent is the growing pressure on Australia’s healthcare system. As the population ages and medical technology advances, costs will only continue to rise. If we don’t act now, we risk creating a two-tier system where only the wealthy can afford quality care.
Final Thoughts
As I reflect on this issue, what strikes me most is how avoidable it all seems. This isn’t a problem without a solution; it’s a problem without the political will to solve it. Personally, I think the Australian public deserves better. They deserve a healthcare system that’s fair, transparent, and focused on their needs, not the bottom line of multinational corporations.
If you take a step back and think about it, this isn’t just about medical devices—it’s about the kind of society we want to live in. Do we accept a system where profit trumps health, or do we demand something better? The choice, ultimately, is ours.
